ARTICLE | Deals
Novo to use Ascendis’ TransCon for once-monthly GLP-1R agonist
Deals report: AbbVie-EvolveImmune, Genmab-Revitope and GSK-Chimagen partner for T cell engagers
November 5, 2024 2:03 AM UTC
With competition on the way, Novo Nordisk gained access to a conjugation technology from Ascendis that will help the pharma develop a once-monthly GLP-1R agonist for obesity and Type II diabetes.
Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) agreed to pay $100 million up front plus potential milestones to use the TransCon transient conjugation technology of Ascendis Pharma A/S (NASDAQ:ASND)...